Media Coverage

SfN Presentations Provide Insights on Brain-Related Diseases

11/21/2016

Scientists have a deep understanding of the strengths and shortcomings of research models, which gives them insight when validating new compounds. This has ultimately helped lead the charge in developing more complex models for neuroscience research. Patrick Sweeney from Charles River discusses in GEN.

Cell-Line Denial Is Too Costly, Authenticate!

11/15/2016

A 2013 study reported that only 43% of cell lines could be uniquely identified, indicating that cell line authentication is crucial to understanding and documenting materials used in biopharmaceutical production. Dr. Debbie Letham from Charles River discusses in GEN.

Mouse with a milkshake: Behavioral windows into brain function

11/04/2016

Researchers are teaching mice to nose-poke a touchscreen by doling out strawberry milkshakes as part of cognitive testing, a technique they hope will help in the development in translational therapies for diseases like Alzheimer’s. Maksym Kopanitsa, Head of Translational Biology, discusses the concept in Science.

Quantitative HRMS in the Age of Biologics

10/25/2016

It is a commonly encountered view from the quantitative bioanalysis community that high resolution mass spectrometry (HRMS) is a qualitative technique employed by biotransformation chemists working in “the other” mass spectrometry laboratory. Read more from ​Iain Love of Charles River in BioAnalysis Zone.

Humanizing Animals for Immuno-Oncology

10/15/2016

Despite great progress, most newly developed anticancer agents fail clinical trials, mainly due to the use of inappropriate preclinical models. In this context, patient-derived-xenograft (PDX) models has regained interest over the last decade. Vincent Vuaroqueaux, Ph.D. from Charles River discusses in GEN.

The Human Parts of Mouse Models

10/11/2016

Recently, there has been a push in cancer research to establish and characterize large collections of patient-derived tumor xenograft (PDX) models—mice implanted with cancerous tissue from human patients. Learn more from Julia Schueler, DVM, PhD, and Head of In Vivo Operations at Charles River.

The LAL Industry's Invaluable Partner

09/20/2016

In modern history, endotoxin testing has improved the safety of drugs and medical devices around the world, and the horseshoe crab has been a vital part of that improvement. John Dubczak, General Manager of Charles River's Microbial Solutions Division, discusses in Outsourced Pharma.

James Foster Interview on Mad Money with Jim Cramer

09/12/2016

In an exclusive interview, CNBC’s Jim Cramer spoke with James Foster, chairman, president and CEO of Charles River Laboratories, about the Company’s growth plans, drug prices and the future of cancer research.

Charles River Laboratories is first CRO to join U.K.-based research consortium

08/22/2016

Charles River Laboratories is the first full-service contract research organization (CRO) to join the U.K.-based, international Milner Therapeutics Institute and Consortium. The Milner Therapeutics Institute and Consortium is a collaborative matchmaking service established in 2015 that connects academic research centers, pharmaceutical companies and the industry’s leading scientists in an effort to accelerate research and improve outcomes for patients.

Displaying results 1-10 (of 73)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8  >  >|